+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Pipeline Review of Glioblastoma Treatment Market Expected to Reach USD 0.91 Billion in 2022

Posted on Jun 10, 2015

According to a new market report published by Transparency Market Research “Pipeline Review of Glioblastoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022,” the global glioblastoma treatment market was valued at USD 0.34 billion in 2013 and is estimated to reach USD 0.91 billion by 2022 at a CAGR of 11.4% from 2014 to 2022.

 

Browse the full Pipeline Review of Glioblastoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 report at https://www.transparencymarketresearch.com/pipeline-review-of-glioblastoma-treatment-market.html

 

Glioblastoma multiforme (GBM) is a rapid-growing and most invasive form of glioma that develops from star-shaped glial cells (astrocytes and oliodedrocytes) that support health of the nerve cells within the brain. The treatment options available for GBM are surgeries, radiation therapy, chemotherapy and stereotactic radiosurgery. The primary objective of a surgery is to remove as much of the tumor as possible without injuring the surrounding normal brain tissues required for normal neurological functions. However, aggressive invasion, migration, and infiltration of tumor cells in healthy cells makes it impossible to remove the tumor completely from the sight. Hence, chemotherapy is used to shrink the tumor or as a post-surgery treatment to irradiate remaining cancer cells. Radiation therapy also helps to control the growth of the tumor and may be used instead of or in addition to the surgery. According to the experts, chemotherapy and radiation therapy helps to extend the overall survival period of GBM patient to approximately one year. Thus, the treatments such as temozolomide, carmustine and bevacizumab are most effective against GBM than any other available treatments. 

 

                            

Carmustine drug is brand named as Gliadel (Arbor Pharmaceuticals, LLC) which is a surgical implant, while bevacozumab (Brand name Avastin, product of Genetech/ Roche) is targeted for intravenous therapy and temozolomide (Temodar/ Temodal/ Temcad and other brands) is recommended for intravenous or oral chemotherapy. Temozolomide, (TMZ) (brand names Temodar/ Temodal/ Temcad) is an alkylating agent used for the treatment of Grade IV astrocytoma (GBM). It is the most preferred treatment combined with surgery or radiotherapy that accounted for the highest market share in GBM treatment market. Temozolomide lost its market share after losing its market exclusivity in 2012, which was later cannibalized by more efficient monoclonal antibody, bevacizumab (Avastin). Therefore, in the near future bevacizumab is expected to surpass the temozolomide revenues in GBM treatment market. As per the guidelines of National Institute for Health and Care Excellence (NICE), carmustine implants are recommended as a possible treatment for people with newly diagnosed high-grade glioma only if 90% or more of their tumor has been removed. Due to invasive applications carmustine compared to temozolomide and bevacizumab, carmustine accounts for the lowest market share in GBM treatment market.

 

The phase III of GBM treatment pipeline comprises two most promising products of the future GBM market; namely Rindopepimut or CDX-110 (Celldex Therapeutics) and DCVax-L (Northwest Biotherapeutics). These two molecules have performed well in phase II clinical trials in terms of exceeding the overall survival period for patients. There are more than 50 drug candidates in phase I and phase II clinical trials including biologics, small molecules, devices, surgeries, and immunotherapy. The established companies of GBM market are F. Hoffman-La Roche, Arbor Pharmaceuticals, LLC and Merck & Co., while Celldex Therapeutics and Northwest Biotherapeutics are the new players that are expected to lead the GBM market.

 

The pipeline review of glioblastoma treatment market has been segmented as below:

  • Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs
    • Bevacizumab (Avastin)
    • Temozolomide (Temodar and Temodal and Temcad)
    • Carmustine (BiCNU)
  • Global Glioblastoma Treatment Market Revenue and Forecast, by Geography
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World
  • Global Pipeline Review of Glioblastoma Treatment
    • Overview
    • Late Stage (Phase III)
      • DCVax
      • Rindopepimut (CDX-110)
      • Others
    • Early Stage (Phase I, II and Pre clinical)
      • ABT-414
      • MM-398
      • ARC-100
      • AV0113
      • Cotara
      • Crenolanib
      • SGT-53
      • Endostatin
      • ANG1005
    • Others

 

About Us

 

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. 

 

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

 

Contact

 

Mr.Sudip S
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

Back To Top